Lonza Group Ltd - Company Profile
Powered by
All the data and insights you need on Lonza Group Ltd in one report.
- Save hours of research time and resources with
our up-to-date Lonza Group Ltd Strategy Report
- Understand Lonza Group Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Lonza Group Ltd (Lonza) is a contract manufacturing and development solutions company. It offers services including commercial mammalian and microbial manufacturing, clinical development, and manufacturing. It also offers high-potential active pharmaceutical ingredients, cell and gene therapy capabilities, advanced intermediates, oral drug product development services, cell-culture modeling, genome editing, endotoxin products, and research media and testing products. Lonza provides solutions for health and well-being, microbial and hygiene control, and composites and material protection. Lonza serves biotechnology, pharmaceutical, academic, and government research industries; manufacturers of health and consumer products; formulators and service companies. The company operates manufacturing and R&D facilities in Asia, Europe, and the Americas. Lonza is headquartered in Basel, Switzerland.
Lonza Group Ltd premium industry data and analytics
Products and Services
Products | Services | Brands |
---|---|---|
Biologics: | Development Technologies | - |
Mammalian | GS Xceed Gene Expression System | Aldo |
Microbial | XS Technologies for Microbial Expression | Biovert |
XYZ | XYZ | XYZ |
XYZ | XYZ | XYZ |
XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Contracts/Agreements | In April, the company entered into a collaboration agreement with Acumen Pharmaceuticals to manufacture sabirnetug (ACU193) for clinical development and commercialization. |
2024 | Contracts/Agreements | In March, the company entered into an agreement to acquire the Genentech manufacturing facility in Vacaville from Roche for US$1.2 billion. |
2024 | Contracts/Agreements | In March, the company entered into a collaboration with FDX Fluid Dynamix (FDX) and Fraunhofer Institute for Production Systems and Design Technology IPK to increase the development of messenger RNA (mRNA) based therapies. |
Competitor Comparison
Key Parameters | Lonza Group Ltd | DSM-Firmenich AG | Dottikon ES Holding AG | Mabuhay Vinyl Corp | Actelion Pharmaceuticals Ltd |
---|---|---|---|---|---|
Headquarters | Switzerland | Switzerland | Switzerland | Philippines | Switzerland |
City | Basel | Kaiseraugst | Dottikon | Makati | Allschwil |
State/Province | - | - | - | - | Basel-Landschaft |
No. of Employees | 18,000 | 29,301 | 694 | 153 | - |
Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Albert M. Baehny | Chairman | Executive Board | 2018 | 71 |
Philippe Deecke | Chief Financial Officer | Senior Management | 2021 | 51 |
Caroline Barth | Chief Human Resources Officer | Senior Management | 2020 | 51 |
Christoph Mader | Vice Chairman | Executive Board | 2020 | 64 |
Christian Seufert | President - Capsules and Health Ingredients Division | Senior Management | 2022 | 48 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer